|
Peregrine Pharmaceuticals Shows Strong Potential for Tarvacin |
|
|
|
|
Monday, 03 April 2006 |
Peregrine Pharmaceuticals Shows Strong Potential for Tarvacin
 LOS ANGELES, CA, (NAMC) - The Tustin, California based biopharmaceutical company, Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), shows strong potential for Tarvacin as they presented it at the 97th Annual Meeting of the American Association for Cancer Research.
The company demonstrated that a mouse equivalent to its first-in-class anti-phospholipid agent Tarvacin showed a higher survival rate in cisplatin-resistant breast cancer and radiotherapy-resistant brain cancer when given as part of a combination regimen.
This is positive news for the company and should show evidence of this in today’s trading session.
This article can be republished either online or in print as long as credit is given to the author and the NAMC Newswire. NAMC Newswire articles can now be listened to on StreetIQ.com http://www.streetiq.com/dir/NAMC.shtml
To keep up to date with companies that we report on just register to receive the FREE Wall Street to Main Street Daily Newsletter. We feature companies that trade on the NYSE, AMEX, NASDAQ, OTCBB and Overseas, Keeping our readers informed daily. Just go to our site and register, it’s simple and free, www.namcnewswire.com/newsletter . Also be sure to visit the NAMC radio at www.namcnewswire.com/namcradio for the latest reports, interviews and corporate updates featured on the NAMC Newswire.
|
|
NAMC News 
